Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib Combined with Pyrotinib in Advanced Esophageal Squamous Cell Carcinoma
NCT06684600Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib, pyrotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Started Nov 2024; status: recruiting.
02
Drugs
dalpiciclibpyrotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06684600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684600.